je.st
news
Approval of new antibiotic by Cubist to help in $100 trillion global fight
2014-12-22 17:40:08| Biotech - Topix.net
Friday's FDA approval of the latest new antibiotic by Cubist Pharmaceuticals is a step toward combating a problem estimated to kill 10 million people and cost $100 trillion globally by 2050. Late Friday, U.S. regulators gave the nod to Zerbaxa, formerly known by the generic name of ceftolozane/tazobactam, for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections caused by certain so-called Gram-negative bacteria, typically considered among the hardest to kill.
Tags: global
fight
approval
antibiotic
Category:Biotechnology and Pharmaceuticals